Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 222

The DOI matches its Crossref record.

Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma

Open access
Decaens, Thomas, Roudot‐Thoraval, Françoise, Bresson‐Hadni, Solange, Meyer, Carole, Gugenheim, Jean, Durand, Francois, Bernard, Pierre‐Henri, Boillot, Olivier, Boudjema, Karim, Calmus, Yvon, Hardwigsen, Jean, Ducerf, Christian, Pageaux, Georges Philippe, Dharancy, Sebastien, Chazouilleres, Olivier, Dhumeaux, Daniel, Cherqui, Daniel, Duvoux, Christophe·2005·Liver Transplantation

Abstract

The actual impact of transarterial chemoembolization before liver transplantation (LT) for hepatocellular carcinoma (HCC) on patient survival and HCC recurrence is not known. Between 1985 and 1998, 479 patients with HCC in 14 French centers were evaluated for LT. Among these 479 patients, this case-control study included 100 patients who received transarterial chemoembolization before LT (TACE group) and 100 control patients who did not receive chemoembolization (no-TACE group). Patients and controls were matched for the pre-LT tumor characteristics, the period of transplantation, the time spent on the waiting list, and pre- and posttransplantation treatments. Kaplan-Meier estimates were calculated 5 years after LT and were compared with the log-rank test. The mean waiting time before LT was 4.2 +/- 3.2 months in the TACE group and 4.3 +/- 4.4 months in the no-TACE group. The median number of TACE procedures was 1 (range: 1-12). Demographic data, median alpha-fetoprotein level (21.6 ng/mL and 22.0 ng/mL, respectively), and pre- and post-LT morphologic characteristics of the tumors did not differ in the TACE and no-TACE groups. Overall 5-year survival was 59.4% with TACE and 59.3% without TACE (ns). Survival rates did not differ significantly between the two groups with respect to the time on the waiting list, the tumor diameter, or the type of TACE (selective or nonselective). In the TACE group, 30 patients had tumor necrosis > or =80% on the liver explant with a 5-year survival rate of 63.2%, compared with 54.2% among their matched controls (P = 0.9). In conclusion, with a mean waiting period of 4.2 months and 1 TACE procedure, pre-LT TACE does not influence post-LT overall survival and disease-free survival.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/lt.20418

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 222

Metadata

Authors
Decaens, T., Roudot‐Thoraval, F., Bresson‐Hadni, S., Meyer, C., Gugenheim, J., Durand, F., Bernard, P., Boillot, O., Boudjema, K., Calmus, Y., Hardwigsen, J., Ducerf, C., Pageaux, G. P., Dharancy, S., Chazouilleres, O., Dhumeaux, D., Cherqui, D., & Duvoux, C.
Venue
Liver Transplantation
Published
2005-06-22
Volume
11
Issue
7
Pages
767-775
ISSN
  • 1527-6465 (ISSN-L)
  • 1527-6473
OpenAlex
W2059079639
Cited by
222
References
0
FWCI
10.86
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. https://app.cochat.ai/papers/10.1002/lt.20418
The paper
Decaens, T., Roudot‐Thoraval, F., Bresson‐Hadni, S., Meyer, C., Gugenheim, J., Durand, F., Bernard, P., Boillot, O., Boudjema, K., Calmus, Y., Hardwigsen, J., Ducerf, C., Pageaux, G. P., Dharancy, S., Chazouilleres, O., Dhumeaux, D., Cherqui, D., & Duvoux, C. (2005). Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transplantation. https://doi.org/10.1002/lt.20418

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.